EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Effects of Semaglutide on Body Composition and GFR

Hiddo J L Heerspink iD, Maria Soler iD, Jelle M Beernink iD, Niels Jongs iD, Secundino Cigarran, Josep M Cruzado iD, Maria Jesús Puchades, Marina López-Martínez, Ellen Apperloo iD, Femke Waanders iD, Gozewijn D Laverman iD, Annemarie van der Aart-van der Beek iD und 7 weitere

Clinical Journal of the American Society of Nephrology · 2026

DOI: 10.2215/cjn.0000001051 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Journal of the American Society of Nephrology, 2026. Verfasst von Hiddo J L Heerspink und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Body Composition, Glomerular Filtration Rate, Glucagon-Like Peptides, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Key Points Treatment with semaglutide compared with placebo for 24 weeks reduced lean body mass and fat mass in adults with CKD and overweight or obesity. Changes in lean body mass or fat mass during semaglutide treatment did not correlate with changes in creatinine or cystatin C‑eGFR or measured GFR. Semaglutide significantly reduced extracellular water and BP, and changes in BP correlated with extracellular water.

Background

The glucagon-like peptide-1 receptor agonist semaglutide reduces hemoglobin A1c, body weight, BP, and GFR decline. Semaglutide may influence serum creatinine and cystatin C levels by nonkidney-related mechanisms and thereby affect eGFR. We studied the relationship between changes in body composition, eGFR and measured GFR (mGFR), and BP during semaglutide treatment.

Methods

We performed a prespecified analysis of a randomized placebo-controlled double-blind clinical trial in 101 adults with CKD with overweight status or obesity and without type 2 diabetes. Participants were randomized to 24 weeks of semaglutide 2.4 mg/wk subcutaneously or matched placebo treatment. We measured GFR with iohexol clearance, estimated GFR with creatinine and cystatin C, and used bioimpedance spectroscopy to determine lean body mass, fat mass, and extracellular water.

Results

After 24 weeks of treatment, semaglutide compared with placebo changed total body weight, lean body mass, and fat mass by −9.1 (95% confidence interval [CI], −11.0 to −7.2), −2.5 (95% CI, −6.6 to 1.6), and −3.9 (95% CI, −7.8 to 0.0) kg, respectively. No correlations were present between changes in total body weight, lean body mass, and fat mass with changes in eGFR (creatinine or cystatin C) or mGFR during semaglutide treatment (all Spearman correlation coefficients

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Body CompositionGlomerular Filtration RateGlucagon-Like PeptidesHypoglycemic AgentsKidneyOverweightRenal Insufficiency, ChronicAdultAgedFemaleHumansMaleMiddle AgedBlood PressureCreatinineCystatin CDouble-Blind MethodObesitySemaglutide

Stichwörter der Autor:innen

CKDGLP-1 receptor agonistsclinical trialcreatinine clearancelean body massmechanismsobesityrandomized controlled trials

Substanzen

CreatinineCystatin CGlucagon-Like PeptidesHypoglycemic AgentsSemaglutide

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
  • Department of Nephrology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research, Barcelona, Spain.
  • Nephrology Service Hospital Ribera-Polusa Lugo, Lugo, Spain.
  • Department of Nephrology, Hospital Universitari Bellvitge, Bellvitge Biomedical Research Institute, University of Barcelona, Barcelona, Spain.
  • Department of Nephrology, University Clinical Hospital, INCLIVA, University of Valencia, Valencia, Spain.

ORCID-Profile: Hiddo J L Heerspink, Maria Soler, Jelle M Beernink, Niels Jongs, Josep M Cruzado, Ellen Apperloo, Femke Waanders, Gozewijn D Laverman, Annemarie van der Aart-van der Beek, André P van Beek, Sofia B Ahmed, Roland E Schmieder, Christoph Wanner, José L Górriz

Förderung

  • Novo Nordisk

Zitieren

APA

Heerspink, H. J. L., Soler, M., Beernink, J. M., Jongs, N., Cigarran, S., Cruzado, J. M., Puchades, M. J., López-Martínez, M., Apperloo, E., Waanders, F., Laverman, G. D., van der Aart-van der Beek, A., van Beek, A. P., Verhave, J. C., Ahmed, S. B., Schmieder, R. E., Wanner, C., Cherney, D. Z. I., & Górriz, J. L. (2026). Effects of Semaglutide on Body Composition and GFR. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.0000001051

Vancouver

Heerspink HJL, Soler M, Beernink JM, Jongs N, Cigarran S, Cruzado JM, et al. Effects of Semaglutide on Body Composition and GFR. Clinical Journal of the American Society of Nephrology. 2026. doi:10.2215/cjn.0000001051

BibTeX
@article{Heerspink2026,
  author = {Heerspink, Hiddo J L and Soler, Maria and Beernink, Jelle M and Jongs, Niels and Cigarran, Secundino and Cruzado, Josep M and Puchades, Maria Jesús and López-Martínez, Marina and Apperloo, Ellen and Waanders, Femke and Laverman, Gozewijn D and van der Aart-van der Beek, Annemarie and van Beek, André P and Verhave, Jacobien C and Ahmed, Sofia B and Schmieder, Roland E and Wanner, Christoph and Cherney, David Z I and Górriz, José L},
  title = {Effects of Semaglutide on Body Composition and GFR},
  journal = {Clinical Journal of the American Society of Nephrology},
  year = {2026},
  doi = {10.2215/cjn.0000001051}
}
Kostenlos starten →